Studying treatment responses in lymphoma-related HLH
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lymphoma and you meet at least one HLH warning sign group:
- Either you meet 5 out of 8 standard HLH diagnostic criteria, or
- Your blood tests show both high sCD25 and high ferritin (OHI index positive).
- Your HLH began within 1 month of your lymphoma diagnosis (especially for aggressive lymphoma).
- Your medical records include enough information about your treatment and response for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for a DNA marker in people with HLH caused by lymphoma. It may help doctors better confirm the cause of HLH and guide treatment decisions.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study is a disease registry that collects medical information from children who have hemophagocytic lymphohistiocytosis (HLH) or are suspected to have it. It helps doctors better understand HLH and how it affects patients over time.
This study follows people with newly diagnosed non-Hodgkin lymphoma to collect information about how they respond to treatment. It aims to improve understanding and care for this type of blood cancer.
This trial looks at how well a measurement called the OHI Index works for people with blood cancers. It may help doctors better assess risk or needs, but it mainly focuses on validating the tool rather than testing a new drug.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.